COPOVIDONE-BASED HOT-MELT EXTRUDED INDOMETHACIN CAPSULES: OPTIMIZED AMORPHOUS FORMULATION ACHIEVING ENHANCED DISSOLUTION AND IMPROVED ORAL BIOAVAILABILITY
DOI:
https://doi.org/10.22159/ijap.2026v18i3.57709Keywords:
Hot-melt extrusion, Copovidone, Indomethacin, Amorphous solid dispersion, Capsule formulation, Solubility enhancementAbstract
Objective: Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) classified asa biopharmaceutics classification system (BCS) Class II drug, characterized by low aqueous solubility and high permeability. Its poor solubility results in dissolution rate-limited and variable oral absorption. To overcome this limitation, the present study aimed to develop and optimize a copovidone-based capsule formulation using hot-melt extrusion (HME) to enhance dissolution and oral absorption.
Methods: Copovidone was selected as the polymer of choice following an initial screening. A two-factorial experimental design was employed to optimize the critical HME process parameters. The prepared extrudates were characterized using powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), and Fourier-transform infrared spectroscopy (FTIR) to assess the solid-state characteristics of indomethacin and potential drug–polymer interactions. The optimized extrudate was filled into capsules and evaluated for mechanical strength, in vitro dissolution performance, and accelerated stability (40 ± 2 °C and 75 ± 5% relative humidity for 3 months) in accordance with International Council for Harmonization (ICH) guidelines. Pharmacokinetic studies were conducted in male Sprague–Dawley (SD) rats, and plasma drug concentrations were quantified using a validated liquid chromatography–tandem mass spectrometry (LC–MS/MS) method.
Results: The optimized formulation demonstrated a significant improvement in aqueous solubility and a faster dissolution rate compared to the pure drug and marketed tablet (p < 0.05). PXRD and DSC analyses confirmed the complete conversion of indomethacin into an amorphous form within the copovidone matrix, whereas FTIR analysis indicated the absence of detrimental drug–polymer interactions. Pharmacokinetic evaluation revealed a faster absorption rate, characterized by a 1.16-fold increase in maximum plasma concentration (Cmax) and a markedly reduced time to reach (Tmax), indicating rapid early systemic exposure. Stability studies confirmed the maintenance of the amorphous state and dissolution performance throughout the storage period.
Conclusion: The findings demonstrate that copovidone-based hot-melt extrusion is an effective strategy for improving solubility, dissolution, and the rate of oral absorption of poorly water-soluble indomethacin, leading to enhanced early systemic exposure.The optimized amorphous capsule formulation shows strong potential for further pharmaceutical development and commercialization in the future.
References
1. Patil H, Tiwari RV, Repka MA. Hot-melt extrusion: from theory to application in pharmaceutical formulation. AAPS PharmSciTech. 2016;17(1):20–42. doi:10.1208/s12249-015-0360-7.
2. Lang B, McGinity JW, Williams RO III. Hot-melt extrusion—basic principles and pharmaceutical applications. Drug Dev Ind Pharm. 2014;40(9):1133–1155. doi:10.3109/03639045.2013.838577.
3. Li X, Hong X, Shuai S, Han X, Li C, Zhang H, et al. A review of hot melt extrusion technology: advantages, applications, key factors and future prospects. Drug Deliv Sci Technol. 2024;98:105884. doi:10.1016/j.jddst.2024.105884.
4. Domsta V, Boralewski T, Ulbricht M, Schick P, Krause J, Seidlitz A. Stability of dexamethasone during hot-melt extrusion of filaments based on Eudragit RS, ethyl cellulose and polyethylene oxide. Int J Pharm X. 2024;8:100263. doi:10.1016/j.ijpx.2024.100263.
5. Tan DK, Maniruzzaman M, Nokhodchi A. Advanced pharmaceutical applications of hot-melt extrusion coupled with fused deposition modelling (FDM) 3D printing for personalised drug delivery. Pharmaceutics. 2018;10(4):203.6. Tambe S, Jain D, Agarwal Y, Amin P. Hot-melt extrusion: highlighting recent advances in pharmaceutical applications. Drug Deliv Sci Technol. 2021;63:102452. doi:10.1016/j.jddst.2021.102452.
7. Samineni R, Chimakurthy J, Konidala S. Emerging role of biopharmaceutical classification and biopharmaceutical drug disposition system in dosage form development: a systematic review. Turk J Pharm Sci. 2022;19(6):706–716. doi:10.4274/tjps.galenos.2021.735548. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–420. doi:10.1023/A:1016212804288.
9. Miranda C, Aceituno A, Fernández M, Mendes G, Rodríguez Y, Llauró V, et al. ICH guideline for biopharmaceutics classification system-based biowaiver (M9): toward harmonization in Latin American countries. Pharmaceutics. 2021;13(3):363. doi:10.3390/pharmaceutics13030363.
10. Valizadeh H, Nokhodchi A, Qarakhani N, Zakeri-Milani P, Azarmi S, Hassanzadeh D, et al. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E100. Drug Dev Ind Pharm. 2004;30(3):303–317. doi:10.1081/DDC-120030426.
11. Fu Q, Lu HD, Xie YF, Liu JY, Han Y, Gong NB, et al. Salt formation of two BCS II drugs (indomethacin and naproxen) with (1R,2R)-1,2-diphenylethylenediamine: crystal structures, solubility and thermodynamic analysis. J Mol Struct. 2019;1185:281–289. doi:10.1016/j.molstruc.2019.02.104.
12. Vranić E, Uzunović A. Dissolution studies of physical mixtures of indomethacin with alpha- and gamma-cyclodextrins. Bosn J Basic Med Sci. 2010;10(3):197–203. doi:10.17305/bjbms.2010.2685.
13. Shi NQ, Wang SR, Zhang Y, Huo JS, Wang LN, Cai JH, et al. Hot melt extrusion technology for improved dissolution, solubility and spring–parachute processes of amorphous self-micellizing solid dispersions containing BCS II drugs indomethacin and fenofibrate. Eur J Pharm Sci. 2019;130:78–90. doi:10.1016/j.ejps.2019.01.019.
14. Alshehri SM, Park JB, Alsulays BB, Tiwari RV, Almutairy B, Alshetaili AS, et al. Mefenamic acid taste-masked orally disintegrating tablets with enhanced solubility via molecular interaction produced by hot-melt extrusion technology. Drug Deliv Sci Technol. 2015;27:18–27. doi:10.1016/j.jddst.2015.03.003.
15. Steerlife India Pvt Ltd. Hot-melt extrusion – Omicron 10P [Internet]. Steerlife India Pvt Ltd; [cited 2026 Jan5]. Available from: https://steerworld.com/pharmaceuticals/hot-melt-extrusion/omicron-10p
16. Saerens L, Vervaet C, Remon JP, De Beer T. Process monitoring and visualization solutions for hot-melt extrusion: a review. J Pharm Pharmacol. 2014;66(2):180–203. doi:10.1111/jphp.12123.
17. Andrés A, Rosés M, Ràfols C, Bosch E, Espinosa S, Segarra V, et al. Setup and validation of shake-flask procedures for the determination of partition coefficients (log D) from low drug amounts. Eur J Pharm Sci. 2015;76:181–191. doi:10.1016/j.ejps.2015.05.008.
18. Dinçer Z, Basan H, Göger NG. Quantitative determination of ambroxol in tablets by derivative UV spectrophotometric method and HPLC. J Pharm Biomed Anal. 2003;31(5):867–872. doi:10.1016/S0731-7085(02)00664-7.
19. Ghaderi F, Nemati M, Siahi-Shadbad MR, Valizadeh H, Monajjemzadeh F. DSC kinetic study of the incompatibility of doxepin with dextrose: application to pharmaceutical preformulation studies. J Therm Anal Calorim. 2016;123(3):2081–2090. doi:10.1007/s10973-015-4995-0.
20. Fawcett TG, Gates-Rector S, Gindhart AM, Rost M, Kabekkodu SN, Blanton JR, Blanton TN. A practical guide to pharmaceutical analyses using X-ray powder diffraction. Powder Diffr. 2019;34(2):164–183. doi:10.1017/S088571561900023X.
21. Shah RB, Tawakkul MA, Khan MA. Comparative evaluation of flow for pharmaceutical powders and granules. AAPS PharmSciTech. 2008;9(1):250–258. doi:10.1208/s12249-008-9046-8.
22. Kossor C, Bhat R, Davé RN. Assessing processability of milled HME extrudates: consolidating the effect of extrusion temperature, drug loading, and particle size via non-dimensional cohesion. Int J Pharm. 2024;666:124833. doi:10.1016/j.ijpharm.2024.124833.
23. Taylor PJ, Jones CE, Dodds HM, Hogan NS, Johnson AG. Plasma indomethacin assay using high-performance liquid chromatography–electrospray tandem mass spectrometry: application to therapeutic drug monitoring and pharmacokinetic studies. Ther Drug Monit. 1998;20(6):691–696.
24. Li N, Zhang H, Bai H, Lu K. Development and validation of an LC–MS/MS method for ruxolitinib quantification: advancing personalized therapy in hematologic malignancies. J Pharm Pharm Sci. 2024;27:12905. doi:10.3389/jpps.2024.12905.
25. Gebril SM, Ito Y, Shibata MA, Maemura K, Abu-Dief EE, Hussein MR, et al. Indomethacin can induce cell death in rat gastric parietal cells through alteration of apoptosis- and autophagy-associated molecules. Int J Exp Pathol. 2020;101(6):230–247. doi:10.1111/iep.12370.
26. Srinivasan P, Almutairi M, Youssef AA, Almotairy A, Bandari S, Repka MA. Numerical simulation of screw configurations used during preparation of hot-melt extruded Kollidon and Soluplus-based amorphous solid dispersions containing indomethacin. Drug Deliv Sci Technol. 2023;85:104561. doi:10.1016/j.jddst.2023.104561.
27. Horváth ZM, Lauberte L, Logviss K, Bandere D, Mohylyuk V. Quantification of Soluplus and copovidone polymers in dissolution media: a critical systematic review. Drug Deliv Sci Technol. 2023;89:104998. doi:10.1016/j.jddst.2023.104998.
28. Repka MA, Bandari S, Kallakunta VR, Vo AQ, McFall H, Pimparade MB, et al. Melt extrusion with poorly soluble drugs: an integrated review. Int J Pharm. 2018;535(1–2):68–85. doi:10.1016/j.ijpharm.2017.10.056.
29. Deac A, Qi Q, Indulkar AS, Gao Y, Zhang GGZ, Taylor LS. Dissolution mechanisms of amorphous solid dispersions: a close look at the dissolution interface. Mol Pharm. 2023;20(4):2217–2234. doi:10.1021/acs.molpharmaceut.3c00020.
30. S’ari M, Blade H, Cosgrove S, Drummond-Brydson R, Hondow N, Hughes LP, et al. Characterization of amorphous solid dispersions and identification of low levels of crystallinity by transmission electron microscopy. Mol Pharm. 2021;18(5):1905–1919. doi:10.1021/acs.molpharmaceut.0c00918.
31. Mohsen MM, Patil AB, Kalhandaki MS, Jha DK, Ambalgikar S. Unlocking drug potential by enhancing poor drug solubility and bioavailability through hot-melt extrusion. Int J Pharm Investig. 2024;14(4):117. doi:10.5530/ijpi.14.4.117.
32. Mohsen MM, Patil AB, Alkanad MA, Patil DA. Beyond the horizon: recent advances in hot-melt extrusion techniques and technologies. Int J Appl Pharm. 2024;16(5):12–21. doi:10.22159/ijap.2024v16i5.51425.
33. Mohsen MM, Nagasree K, Patil AB. The development, formulation, and assessment of polyelectrolytic complexes of an anticancer compound (vinorelbine tartrate). Indian J Pharm Educ Res. 2024;58(3):760–770. doi:10.5530/ijper.58.3.84.
34. Rajadhyax AR, Shinde UJ, Desai HA, Mane SH. Hot-melt extrusion in engineering of drug cocrystals: a review. Asian J Pharm Clin Res. 2021;14(8):10–19.
35. Borawake PD, Arumugam KA, Shinde JV. Formulation of solid dispersions for enhancement of solubility and dissolution rate of simvastatin. Int J Pharm Pharm Sci. 2021;13(7):94–100.
Published
How to Cite
Issue
Section
Copyright (c) 2026 Maged Mohammed Abdo Mohsen, Amit B Patil, Anish Kumar A, Manohar S K
This work is licensed under a Creative Commons Attribution 4.0 International License.